Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. - Wikidata - wikimedia - TriplyDB

Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.

Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.

http://www.wikidata.org/entity/Q30471693

about

Thiazolidinediones promote axonal growth through the activation of the JNK pathway PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease Using genetics to enable studies on the prevention of Alzheimer's disease Vascular and metabolic dysfunction in Alzheimer's disease: a review.Nuclear receptors in neurodegenerative diseases.Insulin resistance in Alzheimer's disease.IUGR disrupts the PPARγ-Setd8-H4K20me(1) and Wnt signaling pathways in the juvenile rat hippocampus.Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.Nuclear receptors as therapeutic targets for Alzheimer's disease Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARγ agonism.The association of diabetes and dementia and possible implications for nondiabetic populations.Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1 Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways.Time-dependent behavioral, neurochemical, and metabolic dysregulation in female C57BL/6 mice caused by chronic high-fat diet intake.Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.Neuroprotective effects of sodium hydrosulfide against β-amyloid-induced neurotoxicity.Cognitive enhancing treatment with a PPARγ agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice.PPARγ recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement A review: treatment of Alzheimer's disease discovered in repurposed agents.T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease.PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.Ruthenium red colorimetric and birefringent staining of amyloid-β aggregates in vitro and in Tg2576 mice Insulin receptor β-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory.Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.Central Regulation of Glucose Homeostasis.Research tool: Validation of floxed α7 nicotinic acetylcholine receptor conditional knockout mice using in vitro and in vivo approaches.The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus.PPARγ agonism attenuates cocaine cue reactivity.Acute inhalation of combustion smoke triggers neuroinflammation and persistent anxiety-like behavior in the mouse.

P2860

Q27317282-23EA300D-2BEE-45F9-8847-EBE7216C7D05 Q28069549-2EA5CF2F-069C-411C-A23D-0053DDEB0768 Q28083039-9F022458-AC4F-4714-BE2F-2CDFB448976B Q33562308-41902DB1-48C7-4E20-B719-7042A18B2237 Q34038890-703AD62A-18D0-4464-B9E2-2A21378D208E Q34193337-0A55F343-3D91-4C5D-A5F7-1564533ABC19 Q34580020-D61AD410-C9B9-4819-AA81-0B5E8A9322AC Q34622157-74205B92-DCB7-4AB9-AE94-A74DC43E8606 Q34715551-FE88C4A8-3055-4E90-B986-409254E6EC58 Q35070472-E2D30DCA-CCA2-45AC-BD89-9017607A32C5 Q35165186-0F1B731E-5B71-42A9-A58C-2B96051DF752 Q35178508-E312BCF0-2D2A-4BE3-82AD-40CA3F5BC8DA Q35619553-E00E9654-956B-4A1D-8B53-7727812BEEC4 Q35947448-4AD37376-84A7-4949-94CC-3873FE96C158 Q36044265-CF6E96E8-757D-4C39-8273-E9ED28C7A600 Q36065117-2B88AE6E-AA07-4178-90D7-8DE9E1C4806B Q36208400-033EF324-0E45-43C4-A65C-1548632777D3 Q36616121-6A8F0E57-BE43-42B6-B2E2-C557AD5C56FE Q36665054-1D7B3B29-191F-49D0-A189-A6D667D510BC Q37158071-8C21D981-F05C-43F7-9221-19BDF837B471 Q37164474-991A6F0E-9B34-474A-BF5E-4777F19C7512 Q37269956-9C68C4A7-FAC8-49A9-AA7B-03C9F75ED335 Q37479405-12674EAC-4B53-4751-8027-699754E42562 Q37633627-C19D9212-4DA9-4ED3-8BF3-A3C7BBCB5B8B Q38073138-06216DE5-F44D-4835-8B07-6B2BDE4E2F99 Q38396373-34BD88C2-60FE-49F9-A45D-3B430EB50FE1 Q38688226-FED66B2E-0275-482D-BF4B-B416E4BFD929 Q38776236-C3581BB7-B7AE-4E58-9314-D1D1867679CA Q39164346-F725A733-2200-46FB-8F20-B02CDEC24D22 Q39208627-E913E50B-E18C-4A22-BE9A-B6D3A0E1D017 Q44765030-B3B38CE0-307B-49FB-8089-01F0455CDB59 Q47740742-FFE2803E-6B27-44AD-9EEE-ED0C36D01937 Q48249963-7F1F7212-9981-4220-919E-27EFD12A520C Q48748389-C0984505-0B33-4519-BCE7-7AABB63461A1 Q48901148-BF445F8E-2EA3-47C2-B767-0AD6E2C5AADA Q48930376-DF97F399-57CD-4791-993F-4E4C342D18C2 Q50060495-853E6E27-05A0-45C0-92FA-75013575653D

P2860

Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.

http://www.wikidata.org/entity/Q30471693

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rosiglitazone reversal of Tg25 ...... heral gluco-regulatory status.

@ast

Rosiglitazone reversal of Tg25 ...... heral gluco-regulatory status.

@en

type

label

Rosiglitazone reversal of Tg25 ...... heral gluco-regulatory status.

@ast

Rosiglitazone reversal of Tg25 ...... heral gluco-regulatory status.

@en

prefLabel

Rosiglitazone reversal of Tg25 ...... heral gluco-regulatory status.

@ast

Rosiglitazone reversal of Tg25 ...... heral gluco-regulatory status.

@en

P1433

Q30471693-24212E3D-393B-4A76-8FB0-BFC055050B73

P1476

Q30471693-44532BBB-97A5-4B9A-AC1E-575C3F443577

P2093

Q30471693-CBB6CDE9-12AD-4971-88BA-37AD633BE8FE

Q30471693-DAF03B86-9895-42B3-8232-FDDE89F3207A

Q30471693-FEC6D6BE-35FD-4317-90A9-5AE70203161D

P2860

Q30471693-07D465E5-8116-420F-ABF4-FD48A01843A7

Q30471693-0C13F17E-FA19-4080-AD23-E0CE29674E85

Q30471693-18D12411-0135-41F8-86B7-8E652F6C53D8

Q30471693-20A639C8-CE42-4E8B-8BDD-B50E7A5C2282

Q30471693-2BFE7D3A-B7E2-463E-B387-C374CAB1556D

Q30471693-3196B2C6-F229-4FD0-9E76-4B852071576D

Q30471693-3C0D810E-CCEF-488C-8401-2E807DE46278

Q30471693-4565AC7B-6FA8-4878-B2E5-CDD8EA42CABC

Q30471693-485449DD-8746-406E-AEE0-BD2CF83172BF

Q30471693-583BA9CF-8E06-4F63-9875-E331D4DC0B6B

P304

Q30471693-99D4C250-D9A7-4395-830F-C3010067D540

P31

Q30471693-48BABD1D-8A9E-4505-BCC9-644F2788DF3D

P356

Q30471693-AA0B23CA-4974-4E49-AC1C-82B9D995DAEC

P407

Q30471693-11360276-DC09-48C1-B60B-8CAB012D245F

P433

Q30471693-8098D022-DDA1-4792-B5FD-6D9950F1BEEB

P478

Q30471693-F6B7C1AD-0942-4B20-B0C7-294002147A01

P577

Q30471693-BC72D81C-5EC9-43F7-B9B2-03CB82A20B4F

P5875

Q30471693-75AB84EB-7F0C-41ED-96B0-AEA713F9B50E

P698

Q30471693-D2A01973-831A-4982-AAB9-ED7E8757962A

P932

Q30471693-51AE2865-05B0-4888-9B88-E8E2EFF61F32

P356

J.BBR.2010.08.002

P1433

Behavioural Brain Research

P1476

Rosiglitazone reversal of Tg25 ...... heral gluco-regulatory status.

@en

P2093

Jennifer Rodriguez-Rivera

http://www.w3.org/2001/XMLSchema#string

Kelly T Dineley

http://www.w3.org/2001/XMLSchema#string

Larry Denner

http://www.w3.org/2001/XMLSchema#string

P2860

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Clinical features of Alzheimer's disease

Memantine for dementia

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model.

Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

Insulin and neurodegenerative disease: shared and specific mechanisms.

Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice

P304

255-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBR.2010.08.002

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

216

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45649891

http://www.w3.org/2001/XMLSchema#string

P698

20709114

http://www.w3.org/2001/XMLSchema#string

P932

2975872

http://www.w3.org/2001/XMLSchema#string